Compare AHG & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AHG | DFTX |
|---|---|---|
| Founded | 2013 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2017 | N/A |
| Metric | AHG | DFTX |
|---|---|---|
| Price | $2.00 | $23.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $38.50 |
| AVG Volume (30 Days) | 14.4K | ★ 2.0M |
| Earning Date | 08-14-2025 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.08 | $14.62 |
| 52 Week High | $2.50 | $26.25 |
| Indicator | AHG | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.58 | 69.50 |
| Support Level | $1.57 | $16.37 |
| Resistance Level | $2.46 | N/A |
| Average True Range (ATR) | 0.18 | 1.32 |
| MACD | -0.06 | 0.14 |
| Stochastic Oscillator | 22.03 | 55.08 |
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).